Expanding Medicare’s Rx Abuse Controls Beyond Opioids Is Premature, Diverse Groups Tell CMS
This article was originally published in The Pink Sheet Daily
Commenting on the draft “call letter” for the 2014 Part D plan year, associations representing drug manufacturers, pharmacists and physicians say CMS should first review issues such as how the protocols for the opioids are working and differences between opioids and other classes of drugs.
You may also be interested in...
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.
FDA/CMS Summit speakers say they've yet to see any real interest from manufacturers in putting money at risk if their products don't meet outcome measures.